MERRIMACK PHARMACEUTICALS IN's ticker is MACKXXXX and the CUSIP is 590328100. A total of 130 filers reported holding MERRIMACK PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $58,000 | -52.1% | 18,769 | -36.6% | 0.00% | – |
| Q4 2016 | $121,000 | -30.1% | 29,616 | +8.6% | 0.00% | – |
| Q3 2016 | $173,000 | +31.1% | 27,263 | +11.3% | 0.00% | – |
| Q2 2016 | $132,000 | -30.9% | 24,488 | +7.5% | 0.00% | – |
| Q1 2016 | $191,000 | +61.9% | 22,776 | +52.6% | 0.00% | – |
| Q4 2015 | $118,000 | -65.5% | 14,929 | -62.9% | 0.00% | -100.0% |
| Q3 2015 | $342,000 | -29.9% | 40,221 | +2.0% | 0.00% | 0.0% |
| Q2 2015 | $488,000 | +17.6% | 39,439 | +13.0% | 0.00% | 0.0% |
| Q1 2015 | $415,000 | -0.2% | 34,899 | -5.1% | 0.00% | 0.0% |
| Q4 2014 | $416,000 | +135.0% | 36,791 | +82.0% | 0.00% | – |
| Q3 2014 | $177,000 | +142.5% | 20,210 | +39.8% | 0.00% | – |
| Q1 2014 | $73,000 | -16.1% | 14,453 | -11.5% | 0.00% | – |
| Q4 2013 | $87,000 | +102.3% | 16,330 | +42.7% | 0.00% | – |
| Q3 2013 | $43,000 | – | 11,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 5,000,000 | $20,400,000 | 4.19% |
| Consonance Capital Management LP | 9,067,998 | $36,997,000 | 4.06% |
| Lagoda Investment Management, L.P. | 1,522,529 | $6,212,000 | 2.13% |
| INDUS CAPITAL PARTNERS, LLC | 1,050,000 | $4,284,000 | 0.56% |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 9,072,877 | $37,017,000 | 0.32% |
| GARRISON BRADFORD & ASSOCIATES INC | 77,700 | $317,000 | 0.29% |
| Cannell & Co. | 1,572,978 | $6,418,000 | 0.23% |
| Virtus ETF Advisers LLC | 179,625 | $733,000 | 0.22% |
| LeJeune Puetz Investment Counsel LLC | 3,976 | $161,000 | 0.12% |
| STONERIDGE INVESTMENT PARTNERS LLC | 221,838 | $905,000 | 0.12% |